APA (7th ed.) Citation

Liu, X., Zhao, W., Jia, Y., Shi, Y., Wang, X., Li, S., . . . Tong, Z. A non-inferiority, phase III trial of gemcitabine plus capecitabine gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer. SAGE Publishing.

Chicago Style (17th ed.) Citation

Liu, Xiaodong, et al. A Non-inferiority, Phase III Trial of Gemcitabine Plus Capecitabine Gemcitabine Plus Carboplatin as First-line Therapy and Tumor-infiltrating Lymphocytes as a Prognostic Biomarker in Patients with Advanced Triple-negative Breast Cancer. SAGE Publishing.

MLA (9th ed.) Citation

Liu, Xiaodong, et al. A Non-inferiority, Phase III Trial of Gemcitabine Plus Capecitabine Gemcitabine Plus Carboplatin as First-line Therapy and Tumor-infiltrating Lymphocytes as a Prognostic Biomarker in Patients with Advanced Triple-negative Breast Cancer. SAGE Publishing.